⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEM News
Tempus AI, Inc. Class A Common Stock
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
businesswire.com
TEM
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
businesswire.com
TEM
Tempus Reports Third Quarter 2025 Results
businesswire.com
TEM
Tempus to Participate in the Stifel 2025 Healthcare Conference
businesswire.com
TEM
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
businesswire.com
TEM
WHWK
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
businesswire.com
TEM
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
businesswire.com
TEM
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
prnewswire.com
GTBP
LXEO
ANIX
TEM
CTOR
GTBP
LXEO
ANIX
TEM
CTOR
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
businesswire.com
TEM
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
prnewswire.com
TEM